GlassScriptPhysician profile
Christopher M Griffin
NPI 1831180819
$1,919.48
in general payments reported to CMS, 2019-2025
19 companies · $67.01 in 2025
The $67.01 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $326 · 2021: $25.96 · 2022: $25.60 · 2023: $176 · 2024: $58.59 · 2025: $67.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $304.46 | 2019-2020 | |
| Allergan, INC. | $277.70 | 2019-2020 | |
| Abbvie INC. | $251.77 | 2021-2025 | |
| Novo Nordisk INC | $221.72 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $190.81 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $101.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $101.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $75.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $69.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.05 | 2019 | |
| Lilly USA, LLC | $38.27 | 2019-2022 | |
| Astellas Pharma US INC | $37.08 | 2019-2020 | |
| Amgen INC. | $28.47 | 2019-2020 | |
| Amarin Pharma, INC. | $24.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.60 | 2019 | |
| Axsome Therapeutics, INC. | $16.59 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.